

Rituximab

Essential medicine status

General description

Rituximab is a monoclonal antibody used in treatment protocols for lymphomas and leukaemia, as well as various autoimmune inflammatory diseases.

INN

Rituximab

ATC codes

[L01FA01](#)

Medicine type

Biological agent

EML status history

First added in 2015 ([TRS 994](#)) for [Diffuse large B-cell lymphoma, not otherwise specified](#)

Added in 2015 ([TRS 994](#)) for [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)

Added in 2015 ([TRS 994](#)) for [Follicular lymphoma](#)

Added in 2023 ([TRS 1049](#)) for [Multiple sclerosis](#)

Added in 2023 ([TRS 1049](#)) for [Burkitt lymphoma including Burkitt leukaemia](#)

Wikipedia

[Rituximab](#)

DrugBank

[Rituximab](#)

Recommendations

Section

Targeted therapies

- Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Indications

[Diffuse large B-cell lymphoma, not otherwise specified](#) [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)

[Follicular lymphoma](#) [Burkitt lymphoma including Burkitt leukaemia](#)

Section

Medicines for multiple sclerosis

- Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial

Indications

[Multiple sclerosis](#)